Abstract:Intraocular pressure and aqueous humor formation rate have been determined from the first trimester of pregnancy through term, with further determinations 3 months postpartum, in 7 patients. The intraocular pressure showed a consistent, statistically significant fall during pregnancy, returning to values seen in early pregnancy after delivery. Aqueous humor formation rate showed no change during pregnancy. The data indicate that the sustained elevated hormonal levels during pregnancy, either directly or indire… Show more
“…10,11 Moreover, it has been reported that physiologic changes during pregnancy (especially in late pregnancy) lead to a mild decrease in the IOP compared to the pressure before pregnancy. [12][13][14][15][16][17][18] This change obviates using multiple classes of antiglaucoma medications to control IOP. After delivery, the oral carbonic anhydrase inhibitors were replaced by topical carbonic anhydrase inhibitors and latanoprost in all patients.…”
Background: There are limited data about the effects of anti-glaucoma drugs on pregnancy. The purpose of this study was to observe pregnancies exposed to anti-glaucoma medications. Methods: Six pregnant glaucomatous patients referred to the glaucoma clinic after their first trimesters were advised to continue their medications. In one patient who was on oral acetazolamide, the drug was substituted with topical medications. In the last month of pregnancy acetazolamide was started and all topical medications were stopped. The control group comprised 24 individuals with no systemic disease or exposure to medications and with comparable age and gestational age on delivery. Pregnancy and delivery complications, Apgar scores at one and five minutes, birth weight, congenital anomalies and psychophysical development of children up to two years of age were evaluated. Results: The mean age of the patients was 28.17 years with mean gestational age on delivery of 38.80 weeks. Low birth weight was more common in the case group (p = 0.041). No other side-effects were observed. The one-minute Apgar scores were nine in all newborns and improved to 10 at five minutes. The psychophysical development of all children was normal up to two years after birth. Conclusions: Analysis of pregnancy outcome of six mothers taking topical glaucoma medications showed no adverse effects apart from a small but statistically significant increased risk of having low birth weight.
“…10,11 Moreover, it has been reported that physiologic changes during pregnancy (especially in late pregnancy) lead to a mild decrease in the IOP compared to the pressure before pregnancy. [12][13][14][15][16][17][18] This change obviates using multiple classes of antiglaucoma medications to control IOP. After delivery, the oral carbonic anhydrase inhibitors were replaced by topical carbonic anhydrase inhibitors and latanoprost in all patients.…”
Background: There are limited data about the effects of anti-glaucoma drugs on pregnancy. The purpose of this study was to observe pregnancies exposed to anti-glaucoma medications. Methods: Six pregnant glaucomatous patients referred to the glaucoma clinic after their first trimesters were advised to continue their medications. In one patient who was on oral acetazolamide, the drug was substituted with topical medications. In the last month of pregnancy acetazolamide was started and all topical medications were stopped. The control group comprised 24 individuals with no systemic disease or exposure to medications and with comparable age and gestational age on delivery. Pregnancy and delivery complications, Apgar scores at one and five minutes, birth weight, congenital anomalies and psychophysical development of children up to two years of age were evaluated. Results: The mean age of the patients was 28.17 years with mean gestational age on delivery of 38.80 weeks. Low birth weight was more common in the case group (p = 0.041). No other side-effects were observed. The one-minute Apgar scores were nine in all newborns and improved to 10 at five minutes. The psychophysical development of all children was normal up to two years after birth. Conclusions: Analysis of pregnancy outcome of six mothers taking topical glaucoma medications showed no adverse effects apart from a small but statistically significant increased risk of having low birth weight.
“…In the literature, there is an evidence for a direct effect of endogenous hormonal changes on aqueous humor circulation. [12,13,14,15] Population based studies have shown that IOP is equal between the sexes in ages of 20 to 40 yrs .In older age group, an increase in mean IOP with age is greater in females than males. The use of hormone replacement therapy and the protective effect of endogenous hormones could explain the gender difference.…”
Normal Intraocular pressure (IOP) is an essential prerequisite for the eye to serve its function as a light (Student 't' test, p < 0.001) ('F' test p < 0.001).
“…The increased levels of estrogen, progesterone and other placental hormones during pregnancy may play an important role in maintaining the IOP. 1,[6][7][8] IOP may affect women of childbearing age. A decrease in intraocular pressure has been observed during pregnancy and often persists for few months after delivery.…”
Section: Discussionmentioning
confidence: 99%
“…This result in a gradual, statistically significant fall of the IOP during pregnancy. [6][7][8][9] Progesterone has glucocorticoid antagonistic properties and this antagonistic action helps in the lowering of the IOP. The changes in the aqueous dynamics are consistent with the hypothesis that excess progesterone, during pregnancy, blocks the ocular hypertensive effect of endogenous corticosteroids.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.